Helus Pharma's HLP004 Shows Strong Phase 2 Results in Generalized Anxiety Disorder
Event summary
- Helus Pharma's HLP004 demonstrated a statistically significant (p<0.0001) and clinically meaningful improvement in HAM-A scores by ~10 points over standard of care (SoC) in a Phase 2 study for generalized anxiety disorder (GAD).
- The study showed durable effects sustained through at least 6 months, with 67% responders and 39% of patients in remission at six months.
- HLP004 was generally well-tolerated, with no drug-related serious adverse events recorded.
- The Phase 2 signal detection study involved 36 patients randomized 2-to-1 active-to-placebo to HLP004 20 mg or 2mg, with participants receiving two intramuscular doses three weeks apart.
The big picture
Helus Pharma's positive Phase 2 results for HLP004 come at a time when the mental health sector is increasingly focused on developing novel treatments for conditions like GAD, which has seen no new monotherapy approvals in nearly two decades. The durable efficacy and favorable safety profile of HLP004 position it as a potential game-changer in an underserved market. The company's broader pipeline, including HLP003 for major depressive disorder, further underscores its commitment to addressing critical gaps in mental health treatment.
What we're watching
- Regulatory Pathway
- Whether Helus Pharma can leverage these Phase 2 results to accelerate the regulatory approval process for HLP004, given the lack of approved adjunctive treatments for GAD.
- Market Potential
- The pace at which Helus Pharma can commercialize HLP004, considering the significant unmet need in the GAD market, with over 20 million adults affected in the United States.
- Pipeline Progress
- How the upcoming data release on HLP003 for major depressive disorder in Q4 2026 will impact investor sentiment and the company's valuation.
Related topics